A Phase II, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet
Latest Information Update: 10 Apr 2024
Price :
$35 *
At a glance
- Drugs ZED 1227 (Primary)
- Indications Coeliac disease
- Focus Therapeutic Use
- 12 Mar 2024 Status changed from not yet recruiting to recruiting.
- 09 Jan 2024 Status changed from planning to not yet recruiting.
- 27 Oct 2022 New trial record